A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants

Summary

The aim of this study is to evaluate the safety, tolerability and PK of LY3876602 after administering it as single ascending doses and, following a data review, proceeding to multiple ascending doses in healthy participants. Blood tests will also be performed to check how much LY3876602 gets into the bloodstream and cerebrospinal fluid (CSF) and how long it takes the body to eliminate it. Following the screening visit for Part A, the study will last up to approximately 20 weeks., and a subgroup of participants will consent to CSF collections The study will last up to approximately 28 weeks for Part B. All participants will consent to CSF collections.

Timeline

Start

2023-08-23

Primary completion

2025-09-20

Completion

2025-09-20

Drugs

Indications

No indication recorded.